Irvine, California-based Immunis, Inc. has been selected as one of 40 semifinalists in the $101 million XPRIZE Healthspan competition, earning a $250,000 Milestone 1 award to support further development of its therapeutic platform.
The XPRIZE Healthspan initiative, a seven-year global contest, aims to identify treatments capable of restoring at least 10 years of muscle, cognitive, and immune function in individuals aged 50 to 80, within a one-year treatment period.
Immunis, a clinical-stage biotech firm, is developing multi-active biologics targeting age and disease-related immune dysregulation. The company’s selection as a semifinalist underscores its potential in addressing age-related health challenges.
“Immunis is absolutely thrilled and deeply honored to be recognized as a promising healthcare innovator,” the company stated.
All semifinalist teams will be acknowledged during the XPRIZE Healthspan Award Ceremony and Investor Summit in New York City, scheduled for May 12–14.
